With drug candidates in clinical development for in vitro fertilization, endometriosis and more, this Swiss-based, clinical-stage biopharma company is focused on the creation and commercialization of drug therapies for major women’s health issues. But despite positive sentiment from analysts, insiders and institutional investors, it’s being largely ignored by the market. Here’s the case for establishing a position in this stock ahead of the release of clinical trial results. CLICK HERE.
A Women’s Health Stock Analysts (And Insiders) Are Loving, But The Market Is Ignoring
- by Ashley Hayes